The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Piper Sandler 32nd Annual Virtual Healthcare Conference
https://www.faron.com/investors
Interferon and COVID-19: 'We should be stockpiling'
https://www.healthing.ca/diseases-and-conditions/coronavirus/interferon-and-covid-19-we-should-be-stockpiling-says-researcher?utm_source=twitter&utm_medium=organic_tw&utm_term=&utm_content=&utm_campaign=healthing_promo
... Fish says now it’s just a waiting game when it comes to IFN-a and IFN-B. “We’ve looked at their potential utility against many different viruses,” she says. “And in every scenario, with appropriate dosing and short-term use, the results have been very, very positive.”
Early and fast intravenous interferon to all sick and we all are winners.
https://twitter.com/EricTopol/status/1285979253146660864?s=19
https://t.co/ermYrKPngD?amp=1
Breaking news:
Efficacy and safety of interferon ß-1a in treatment of severe COVID-19: A randomized clinical trial
https://aac.asm.org/content/early/2020/07/08/AAC.01061-20
Results: Between 29th February to 3rd April 2020, 92 patients were recruited that finally 42 patients in the IFN group and 39 patients in the control group completed the study. As primary outcome, time to the clinical response was not significantly different between the IFN and the control groups (9.7 ± 5.8 vs. 8.3 ± 4.9 days respectively, P=0.95). On day 14, 66.7% vs. 43.6% of patients in the IFN group and the control group were discharged, respectively (OR= 2.5; 95% CI: 1.05- 6.37). The 28-day overall mortality was significantly lower in the IFN than the control group (19% vs. 43.6% respectively, p= 0.015). Early administration significantly reduced mortality (OR=13.5; 95% CI: 1.5-118).
Conclusion: Although IFN did not change time to reach the clinical response, adding it to the national protocol significantly increased discharge rate on day 14 and decreased 28-day mortality.
Interferon Plays Pivotal, Inflammatory Role in Severe COVID-19 Cases
https://www.genengnews.com/news/interferon-plays-pivotal-inflammatory-role-in-severe-covid-19-cases/?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20200713&oly_enc_id=6677F1147845I8A
"According to the letter sent by the executive group to national coordinators of the Solidarity Trial, Remdesivir and Interferon beta-1a are the two study drugs which Solidarity Trial is best placed to evaluate definitively for possible effects on mortality, and also decided that the Lopinavir/ritonavir arms will be discontinued. This was because the UK Recovery trial, given its current size, will assess Lopinavir/ritonavir robustly without additional recruitment into Solidarity, the letter stated."
https://indianexpress.com/article/india/after-who-move-22-trial-sites-in-india-to-stop-hcq-research-6465702/
https://www.reuters.com/article/health-coronavirus-who-lopinavir-idUSL8N2DV2Z3
Iran tests ReciGen to treat coronavirus
"He referred to ReciGen as one of the drugs used to treat COVID-19, saying that medicine has had a great impact on the treatment of the patients and its use was permitted by the Ministry of Health and in compliance with the relevant laws."
https://iranpress.com/iran-i148353-iran_tests_recigen_to_treat_coronavirus
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.
https://www.sciencedirect.com/science/article/pii/S1567576920312893
https://www.indiatvnews.com/news/world/top-expert-recommends-triple-antiviral-therapy-in-covid-19-treatment-exclusive-interview-ivan-hung-619586
Good sign for antivirals + interferon